DexCom Inc.

San Diego, CA, United States

DexCom Inc.

San Diego, CA, United States
SEARCH FILTERS
Time filter
Source Type

— The “Continuous Glucose Monitoring Systems Market - Medical Devices Pipeline Assessment, 2017” the report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Continuous Glucose Monitoring Systems pipeline products. Browse the 157 Tables and Figures, 70 Companies, Spread across 268 Pages Report Available at http://www.reportsnreports.com/contacts/discount.aspx?name=958615. Scope of the Report: Extensive coverage of the Continuous Glucose Monitoring Systems under development The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities The report reviews the major players involved in the development of Continuous Glucose Monitoring Systems and list all their pipeline projects The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage The report provides key clinical trial data of ongoing trials specific to pipeline products Recent developments in the segment / industry Companies are mentioned: A. Menarini Diagnostics S.r.l., Abbott Diabetes Care, Inc., Advanced Biosensors-Ohio, Llc, Advanced Medical Electronics Corporation, Arkal Medical, Inc., Bio-Impedance General Ltd., Biorasis, Inc., Biovotion AG, CALISTO MEDICAL, INC. (Inactive), Cardiff University Company, City, University of London, Columbia University, ConvaTec Group Plc, Cyber Medical Ltd., Debiotech SA, DexCom Inc, DirectSens GmbH, Echo Therapeutics Inc, Ecole Polytechnique Federale de Lausanne, eLutions Integrated, EyeSense GmbH, Flowsion A/S, Gili Medical Ltd, Globe Medical Tech Inc, and Others. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=958615. Continuous Glucose Monitoring Systems Market- Recent Developments : Mar 30, 2017: ConvaTec Expands Unomedical Manufacturing Technology Partnership with Medtronic Diabetes to Meet Growing Demand Mar 29, 2017: ConvaTec Group: Directorate changes Mar 28, 2017: Novo Acquires 19.95% Stake in Convatec from Nordic Capital and Avista for USD1.22 Billion Mar 28, 2017: ConvaTec: Proposed Directorate Changes Mar 27, 2017: Integrity Applications Board Appoints John Graham CEO and Chairman, Angela Strand Vice Chairman Mar 24, 2017: Medicare Announces Criteria Covering Dexcom G5 Mobile CGM for All People with Diabetes on Intensive Insulin Therapy Mar 21, 2017: Medtronic Prices Public Offering of 1.7% Notes Due 2019 for USD1 Billion Mar 21, 2017: Medtronic Prices Public Offering of 3.35% Notes Due 2027 for USD850 Million Mar 21, 2017: Medtronic Prices Public Offering of 4.625% Notes Due 2045 for USD150 Million Mar 21, 2017: Tenax Therapeutics Announces Year-End 2016 Financial Results and Provides Corporate Update Mar 14, 2017: PositiveID’s E-N-G Mobile Systems’ 2017 Bookings Through February Total $1.7 Million, Up More than 200% from Prior Quarter Mar 13, 2017: DexCom Appoints Richard Collins to Board of Directors Mar 08, 2017: Tandem Diabetes Care Reports 2016 Financial Results Continuous Glucose Monitoring Systems Market- Recent Developments for 2017, January and February is also mentioned. List of Tables Table 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development Table 2: Continuous Glucose Monitoring Systems - Pipeline Products by Segment Table 3: Continuous Glucose Monitoring Systems - Pipeline Products by Territory Table 4: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path Table 5: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date And more List of Figures Figure 1: Continuous Glucose Monitoring Systems - Pipeline Products by Stage of Development Figure 2: Continuous Glucose Monitoring Systems - Pipeline Products by Territory Figure 3: Continuous Glucose Monitoring Systems - Pipeline Products by Regulatory Path Figure 4: Continuous Glucose Monitoring Systems - Pipeline Products by Estimated Approval Date Figure 5: Continuous Glucose Monitoring Systems - Ongoing Clinical Trials Complete Table of Content is Available at Continuous Glucose Monitoring Systems - Medical Devices Pipeline Assessment, 2017. About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/958615-continuous-glucose-monitoring-systems-medical-devices-pipeline-assessment-2017.html


Global Mobile Healthcare (mHealth) Market by Monitoring Devices, Growth Trends and Forecast to 2021, New Report by iHealthcareAnalyst, Inc. Mobile Healthcare (mHealth) Market by Device Types (Blood Pressure, Blood Glucose, Cardiac Rhythm, Pulse, Sleep Apnea, and Multi-Parameter Monitors) and Forecast 2017-2021 Maryland Heights, MO, April 21, 2017 --( Browse Mobile Healthcare (mHealth) Market by Device Types (Blood Pressure, Blood Glucose, Cardiac Rhythm, Pulse, Sleep Apnea, and Multi-Parameter Monitors) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/mhealth-monitoring-and-diagnostic-medical-devices-market/ The global mobile healthcare (mHealth) market report estimates the market size (Revenue USD million - 2014 to 2021) and composition of this market based on device types (blood pressure, blood glucose, cardiac rhythm, pulse, sleep apnea, and multi-parameter monitors) and forecasts growth trends (CAGR% - 2017 to 2021). The global mobile healthcare (mHealth) market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global mobile healthcare (mHealth) market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. Major players operating in the global mobile healthcare (mHealth) market and included in this report are AT&T, Inc., Bayer HealthCare AG, BioTelemetry, Inc. (CardioNet, Inc.), Boston Scientific Corporation, DexCom, Inc., Dräger AG, F. Hoffmann La-Roche Ltd., Johnson & Johnson, LifeWatch AG, Masimo Corporation, Medtronic, Inc. and Omron Healthcare. 1. Monitoring Device 1.1. Blood Pressure Monitors 1.2. Cardiac Monitors 1.3. Glucose Monitors 1.4. Multi-parameter Monitors 1.5. Pulse Oximeters 1.6. Sleep Apnea Monitors 1.7. Others 2. Geography (Region, Country) 2.1. North America (U.S., Canada) 2.2. Latin America (Brazil, Mexico, Rest of LA) 2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU) 2.4. Asia Pacific (Japan, China, India, Rest of APAC) 2.5. Rest of the World 3. Company Profiles 3.1. Bayer HealthCare AG 3.2. BioTelemetry, Inc. (CardioNet, Inc.) 3.3. Boston Scientific Corporation 3.4. DexCom, Inc. 3.5. Dräger AG 3.6. F. Hoffmann-La Roche Ltd. 3.7. FitBit, Inc. 3.8. Fora Care Inc. 3.9. iHealth Labs, Inc. 3.10. Johnson & Johnson 3.11. LifeWatch AG 3.12. Masimo Corporation 3.13. Medisana AG 3.14. Medtronic, Inc. 3.15. Nonin Medical, Inc. 3.16. Omron Healthcare, Inc. 3.17. Withings, Inc. To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/mhealth-monitoring-and-diagnostic-medical-devices-market/ About Us iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals. In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study. Contact Us iHealthcareAnalyst, Inc. 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043 United States Email: sales@ihealthcareanalyst.com Website: https://www.ihealthcareanalyst.com Maryland Heights, MO, April 21, 2017 --( PR.com )-- Mobile Health (mHealth) is a sub-segment of eHealth consisting mobile communication devices, such as mobile phones, tablet computers and PDAs, for health services and information exchange. mHealth applications include the use of mobile devices in collecting community and clinical health data, delivery of healthcare information to practitioners, researchers, and patients, real-time monitoring of patient vital signs, and direct provision of care (via mobile telemedicine). Mobile Health (mHealth) is most commonly used for the practice of clinical medicine and public health with the usage of mobile phones and tablets. Increasing incidences of chronic diseases and geriatric population, increase in the number of clinical trial groups, home care agencies and disease management companies are some of the factors that are driving the global mobile healthcare (mHealth) market.Browse Mobile Healthcare (mHealth) Market by Device Types (Blood Pressure, Blood Glucose, Cardiac Rhythm, Pulse, Sleep Apnea, and Multi-Parameter Monitors) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/mhealth-monitoring-and-diagnostic-medical-devices-market/The global mobile healthcare (mHealth) market report estimates the market size (Revenue USD million - 2014 to 2021) and composition of this market based on device types (blood pressure, blood glucose, cardiac rhythm, pulse, sleep apnea, and multi-parameter monitors) and forecasts growth trends (CAGR% - 2017 to 2021). The global mobile healthcare (mHealth) market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global mobile healthcare (mHealth) market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.Major players operating in the global mobile healthcare (mHealth) market and included in this report are AT&T, Inc., Bayer HealthCare AG, BioTelemetry, Inc. (CardioNet, Inc.), Boston Scientific Corporation, DexCom, Inc., Dräger AG, F. Hoffmann La-Roche Ltd., Johnson & Johnson, LifeWatch AG, Masimo Corporation, Medtronic, Inc. and Omron Healthcare.1. Monitoring Device1.1. Blood Pressure Monitors1.2. Cardiac Monitors1.3. Glucose Monitors1.4. Multi-parameter Monitors1.5. Pulse Oximeters1.6. Sleep Apnea Monitors1.7. Others2. Geography (Region, Country)2.1. North America (U.S., Canada)2.2. Latin America (Brazil, Mexico, Rest of LA)2.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)2.4. Asia Pacific (Japan, China, India, Rest of APAC)2.5. Rest of the World3. Company Profiles3.1. Bayer HealthCare AG3.2. BioTelemetry, Inc. (CardioNet, Inc.)3.3. Boston Scientific Corporation3.4. DexCom, Inc.3.5. Dräger AG3.6. F. Hoffmann-La Roche Ltd.3.7. FitBit, Inc.3.8. Fora Care Inc.3.9. iHealth Labs, Inc.3.10. Johnson & Johnson3.11. LifeWatch AG3.12. Masimo Corporation3.13. Medisana AG3.14. Medtronic, Inc.3.15. Nonin Medical, Inc.3.16. Omron Healthcare, Inc.3.17. Withings, Inc.To request Table of Contents and Sample Pages of this report visit:https://www.ihealthcareanalyst.com/report/mhealth-monitoring-and-diagnostic-medical-devices-market/About UsiHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.Contact UsiHealthcareAnalyst, Inc.2109, Mckelvey Hill Drive,Maryland Heights, MO 63043United StatesEmail: sales@ihealthcareanalyst.comWebsite: https://www.ihealthcareanalyst.com


News Article | May 15, 2017
Site: www.businesswire.com

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conference: The link to each webcast will be available on the DexCom website at www.dexcom.com by navigating to “Our Company,” then “Investor Relations,” and finally “Events and Webcasts” and will be archived there for future reference. DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.


News Article | May 8, 2017
Site: www.businesswire.com

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM) (“DexCom”) announced today that it intends to offer, subject to market conditions and other factors, $300 million aggregate principal amount of Convertible Senior Notes due 2022 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). DexCom also intends to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $45 million aggregate principal amount of notes solely to cover over-allotments, if any. The notes will be senior, unsecured obligations of DexCom, and interest will be payable semi-annually in arrears. The notes will mature on May 15, 2022, unless earlier converted, repurchased or redeemed in accordance with the terms of the notes. Prior to 5:00 p.m., New York City time, on the business day immediately preceding February 15, 2022, the notes will be convertible at the option of holders of the notes only upon satisfaction of certain conditions and during certain periods, and thereafter, at any time until 5:00 p.m., New York City time, on the business day immediately preceding the maturity date. Upon conversion, the notes may be settled in shares of DexCom’s common stock, cash or a combination of cash and shares of the common stock, at the election of DexCom. Prior to May 15, 2020, the notes will not be redeemable. On or after May 15, 2020, DexCom may redeem for cash all or part of the notes, at its option, if the last reported sale price of DexCom’s common stock has been at least 140% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which DexCom provides notice of redemption. Holders of the notes will have the right to require DexCom to repurchase for cash all or a portion of their notes at 100% of their principal amount, plus any accrued and unpaid interest, upon the occurrence of a fundamental change (as defined in the indenture relating to the notes). DexCom will also be required to increase the conversion rate for holders who convert their notes in connection with certain fundamental changes occurring prior to the maturity date or following delivery by us of a notice of redemption. The interest rate, conversion rate, offering price and other terms are to be determined upon pricing of the notes. DexCom expects to use the net proceeds of the offering of the notes to repay $75 million of borrowings under its existing credit facility and the remainder for general corporate purposes and capital expenditures, including working capital needs and buildout of its manufacturing facility in Arizona. DexCom may also use the net proceeds to expand its current business through in-licensing or acquisitions of, or investments in, other businesses, products or technologies; however, DexCom does not have any commitments with respect to any such acquisitions or investments at this time. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities (including the shares of DexCom’s common stock, if any, into which the notes are convertible) and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. Any offers of the notes will be made only by means of a private offering memorandum. The notes will be offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act. The notes and any shares of DexCom’s common stock issuable upon conversion of the notes have not been and are not expected to be registered under the Securities Act, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from such registration requirements. This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties, including, without limitation, statements regarding DexCom’s proposed offering of the notes and expected use of net proceeds of the offering. Statements containing words such as “could,” “believe,” “expect,” “intend,” “will,” or similar expressions constitute forward-looking statements. Factors that may contribute to such differences include, but are not limited to, risks related to whether DexCom will consummate the offering of the notes on the expected terms, or at all, the anticipated principal amount of the notes, prevailing market and other general economic conditions, whether DexCom will be able to satisfy the conditions required to close any sale of the notes, and the fact that DexCom’s management will have broad discretion in the use of the proceeds from any sale of the notes. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. For information about other potential factors that could affect DexCom’s business and financial results, please review the “Risk Factors” described in DexCom’s Annual Report on Form 10-K for the year ended December 31, 2016 and DexCom’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 filed with the Securities and Exchange Commission, or SEC, and in DexCom’s other filings with the SEC. Except as may be required by law, DexCom does not intend, and undertakes no duty, to update this information to reflect future events or circumstances.


News Article | May 2, 2017
Site: www.prnewswire.com

Ventricular Assist Devices - our new study reveals trends, R&D progress, and predicted revenues Where is the VAD market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover How to Stay Ahead Our 154-page report provides 104 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing VAD market. See how to exploit the opportunities. Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, there are forecasts for 3 Product Types and 3 Applications. In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 12 leading national markets: • North America: • The US • Mexico • Canada The report also includes profiles and forecasts for some of the leading companies in the Ventricular Assist Device market, with a focus on the VAD segment of these companies' operations. There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market. Leading companies and the potential for market growth Overall world revenue for VAD will surpass $900m in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing prevalence of heart disease, and increasing ageing population will increase sales to 2027. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the VAD Market report helps you In summary, our 154-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the world Ventricular Assist Devices market and 2 different segmentations, with 3 product categories and 3 applications - discover the industry's prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 6 regional markets and 12 of the leading national markets - US, Mexico, Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Russia, • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight. Visiongain's study is for everybody needing commercial analyses for the Ventricular Assist device market and leading companies. You find data, trends and predictions. Get our report today Ventricular Assist Device (VAD) Market Forecast 2017-2027: Revenue Prospects by Product Type (LAVD, RVAD, BiVAD), Application (BTT & BTD Therapy, Destination Therapy, BTR Therapy) and Geography. Avoid missing out - get our report now. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)-20-7336-6100 Abbottdiabetescare.Com ABIOMED, Inc. Acelity LP, Inc. Advocate Health Care Network Alere, Inc. ALung Technologies Inc. American Heart Association Animas Corporation Asahi Kasei Medical Co. Ltd. Baxter International, Inc. Bodytel Gmbh Boston Scientific Corp. C.R. Bard, Inc. (New Jersey) Cedars-Sinai Cellnovo Group SA Circulite Inc. CryoLife, Inc. DexCom, Inc. Edwards Lifesciences Corp. Exactech, Inc. Guidant Corporation HeartWare International, Inc. Insulet Corp. International Society For Heart And Lung Transplantation Inc Jarvik Heart Inc. LeMaitre Vascular, Inc. Leviticus-Cardio Ltd. LivaNova Plc Mayo Foundation For Medical Education And Research Medtronic Plc Micromed Cardiovascular Inc. Nipro Corp. NuVasive, Inc. On-X Life Technologies Inc. Option Care Enterprises Inc. Organ Recovery Systems Inc. Peter Brasseler Holdings Llc Presence Prv Health Smith & Nephew Plc St. Jude Medical, Inc. Sunshine Heart, Inc. Teleflex, Inc. Terumo Corp. Terumo Heart Incorporated Thoratec Corporation United Network For Organ Sharing Valtech Cardio Ltd Visualase Inc. Walgreens Infusion Services Inc. World Heart Corporation Zimmer Biomet Holdings, Inc. List of Organizations Advocate Health Care Network American Heart Association Food and Drug Administration (FDA) Health Canada Mayo Foundation For Medical Education And Research Ministry of Health, Labor, and Welfare (MHLW) National Health Service (UK) National Institutes of Health (NIH) Presence Prv Health United Nations United Network For Organ Sharing World Health Organization (WHO) To see a report overview please email Sara Peerun on sara.peerun@visiongain.com


News Article | May 2, 2017
Site: www.prnewswire.co.uk

Ventricular Assist Devices - our new study reveals trends, R&D progress, and predicted revenues Where is the VAD market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there. Discover How to Stay Ahead Our 154-page report provides 104 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing VAD market. See how to exploit the opportunities. Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments. Discover sales predictions for the world market and submarkets Along with revenue prediction for the overall world market, there are forecasts for 3 Product Types and 3 Applications. In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 12 leading national markets: • North America: • The US • Mexico • Canada The report also includes profiles and forecasts for some of the leading companies in the Ventricular Assist Device market, with a focus on the VAD segment of these companies' operations. There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market. Leading companies and the potential for market growth Overall world revenue for VAD will surpass $900m in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing prevalence of heart disease, and increasing ageing population will increase sales to 2027. Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead. How the VAD Market report helps you In summary, our 154-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the world Ventricular Assist Devices market and 2 different segmentations, with 3 product categories and 3 applications - discover the industry's prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 6 regional markets and 12 of the leading national markets - US, Mexico, Canada, Germany, UK, France, Italy, Spain, Japan, China, India, Russia, • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence. Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight. Visiongain's study is for everybody needing commercial analyses for the Ventricular Assist device market and leading companies. You find data, trends and predictions. Get our report today Ventricular Assist Device (VAD) Market Forecast 2017-2027: Revenue Prospects by Product Type (LAVD, RVAD, BiVAD), Application (BTT & BTD Therapy, Destination Therapy, BTR Therapy) and Geography. Avoid missing out - get our report now. To request a report overview of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44-(0)-20-7336-6100 Abbottdiabetescare.Com ABIOMED, Inc. Acelity LP, Inc. Advocate Health Care Network Alere, Inc. ALung Technologies Inc. American Heart Association Animas Corporation Asahi Kasei Medical Co. Ltd. Baxter International, Inc. Bodytel Gmbh Boston Scientific Corp. C.R. Bard, Inc. (New Jersey) Cedars-Sinai Cellnovo Group SA Circulite Inc. CryoLife, Inc. DexCom, Inc. Edwards Lifesciences Corp. Exactech, Inc. Guidant Corporation HeartWare International, Inc. Insulet Corp. International Society For Heart And Lung Transplantation Inc Jarvik Heart Inc. LeMaitre Vascular, Inc. Leviticus-Cardio Ltd. LivaNova Plc Mayo Foundation For Medical Education And Research Medtronic Plc Micromed Cardiovascular Inc. Nipro Corp. NuVasive, Inc. On-X Life Technologies Inc. Option Care Enterprises Inc. Organ Recovery Systems Inc. Peter Brasseler Holdings Llc Presence Prv Health Smith & Nephew Plc St. Jude Medical, Inc. Sunshine Heart, Inc. Teleflex, Inc. Terumo Corp. Terumo Heart Incorporated Thoratec Corporation United Network For Organ Sharing Valtech Cardio Ltd Visualase Inc. Walgreens Infusion Services Inc. World Heart Corporation Zimmer Biomet Holdings, Inc. List of Organizations Advocate Health Care Network American Heart Association Food and Drug Administration (FDA) Health Canada Mayo Foundation For Medical Education And Research Ministry of Health, Labor, and Welfare (MHLW) National Health Service (UK) National Institutes of Health (NIH) Presence Prv Health United Nations United Network For Organ Sharing World Health Organization (WHO) To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

Loading DexCom Inc. collaborators
Loading DexCom Inc. collaborators